Skip to content
The year in biotech M&A activity got off to a promising start at JPM Week with announcements of some multi-billion-dollar deals. The flurry of […]
Multi-billion-dollar deals at JPM Week augur a busy BIO CEO 2025 Read More »
The increased interest in JPM Week this year is an indication of an improved dealmaking environment for biotech, according to experts for the Biotechnology
Buzz around JPM Week partnering bodes well for biotech dealmaking, BIO says Read More »
A dispute panel ruled that Mexico’s planned ban on imports of biotech corn is “not based on relevant scientific principles” and would violate the U.S.-Mexico-Canada
USMCA dispute panel halts Mexico’s ban on biotech corn Read More »
Federal officials said they withdrew plans for new regulation of genetically engineered (GE) crops on U.S. wildlife refuges due to the outcry by numerous
How BIO’s comments affected regulations on genetically engineered crops Read More »
The 10-year-old girl was cheerful and upbeat as she spoke to a group of strangers online, but she was also disarmingly clear-eyed about the
Children with rare diseases advocate for legislation in online panel Read More »
Legislation to increase transparency of pharmacy benefit managers (PBMs), and to reauthorize the Pediatric Priority Review Voucher (PPRV), the Pandemic All Hazards Preparedness Act
Congress set to pass PBM reform and extensions of PPRV, PAHPA, Farm Bill Read More »
Proposed federal rules on exchange of medical data with China and five other “countries of concern” can protect Americans without obstructing the global flow
Data transfer rules don’t have to hamper biotech innovation, BIO says Read More »
Pharmacy benefit managers (PBMs) create unnecessary barriers between patients and the medicine they need, experts explained during a Nov. 25 virtual “Patient Advocacy Coffee
Harms of PBMs explained in BIO Patient Advocacy Coffee Chat Read More »
As biotech breakthroughs enable remarkable advances in treatment and prevention of disease, we need similar levels of innovation in access, so patients benefit from
BIO CEO John F. Crowley calls for innovation in access at Milken Health Summit Read More »
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the
BIO Investor Forum panel breaks down when, what, and why of IPOs Read More »
